Robinhood shares gain on Q2 beat, as user and crypto growth accelerate
On Friday, Argus analysts made adjustments to the price target of Bio-Techne Corp. (NASDAQ:TECH), bringing it down to $65.00 from the previous target of $90.00. Despite the reduction, they maintained a Buy rating on the company’s shares.
The revised price target reflects a significant decrease but the Buy rating suggests that the analysts still see potential in the company’s stock. The analysts did not provide specific reasons for the adjustment in the price target for Bio-Techne.
In a separate analysis, the Argus analysts shared their perspective on Markel Corp . (NYSE:MKL), maintaining a Hold rating on the company’s shares. They cited the company’s inconsistent results and return on equity (ROE) measures as reasons for not recommending the stock at this time. However, they acknowledged Markel’s commitment to underwriting profitability and strategic acquisitions. According to InvestingPro data, Markel maintains a "Great" Financial Health Score of 3.07, with strong liquidity metrics and a market capitalization of $24.3 billion. The company generated revenues of $15.5 billion in the last twelve months.
Despite the lack of a dividend—which is notable given the industry average yield of about 1.8%—the analysts believe that Markel’s current valuation metrics fairly represent its prospects for solid growth in insurance premiums. InvestingPro analysis confirms the company’s no-dividend policy but highlights its strong five-year return performance. Trading at a P/E ratio of 14.07 and price-to-book of 1.46, the company faces challenges including inconsistent ROE, headwinds in the investment portfolio, and fluctuating equity valuations.
The analysts indicated that they may reconsider their rating for Markel, potentially moving it back to their Buy list, if the company demonstrates consistent improvement in ROE or decides to initiate a dividend payment. For deeper insights into Markel’s financial health and growth prospects, investors can access the comprehensive Pro Research Report, available exclusively on InvestingPro, which provides detailed analysis of the company’s performance metrics and future potential.
In other recent news, Markel Group Inc. reported disappointing first-quarter 2025 earnings, missing both earnings per share (EPS) and revenue forecasts. The company posted an EPS of $12.08, significantly lower than the expected $17.4, and revenue of $3.4 billion, falling short of the projected $3.89 billion. Despite these challenges, Markel remains optimistic about premium acceleration in the latter half of 2025. In a separate development, Markel announced a leadership change in its UK operations, with Lee Mooney set to take over as managing director, pending regulatory approval. Additionally, Markel held its annual shareholder meeting where all nominated directors were elected, and KPMG LLP was ratified as the independent auditor. Shareholders approved executive compensation but rejected a proposal for a report on greenhouse gas emissions. These developments reflect Markel’s ongoing efforts to navigate a challenging financial landscape while maintaining a focus on governance and operational efficiency.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.